The Consultant & Investment GroupAMM:CICO 77 EBITDA Margin % is 15.28% as of Mar. 2026, which is 52% above its 10-year median of 10.07. GuruFocus rates AMM:CICO with a GF Score™ of 77/100 and a GF Value™ of JOD2.20 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, The Consultant & Investment Group ranks better than 67.37% on this metric.
The Consultant & Investment Group (AMM:CICO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
The Consultant & Investment Group EBITDA Margin % Related Terms
The Consultant & Investment Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Consultant & Investment Group EBITDA Margin % Chart
AMM:CICO vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, The Consultant & Investment Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Consultant & Investment Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Consultant & Investment Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where The Consultant & Investment Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Consultant & Investment Group (AMM:CICO) has a EBITDA Margin % of 15.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Consultant & Investment Group and its competitors. This is 52% above median its historical median of 10.07. According to the industry distribution chart, The Consultant & Investment Group ranks #218 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 32.6%.
Is The Consultant & Investment Group's EBITDA Margin % too high?
The Consultant & Investment Group's current EBITDA Margin % of 15.28% is 52% above median its 10-year median of 10.07. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. The Consultant & Investment Group's value of 15.28% is 49.7% above this industry median. Based on the distribution chart, The Consultant & Investment Group ranks #218 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Consultant & Investment Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Consultant & Investment Group's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, The Consultant & Investment Group ranks #218 out of 668 companies for EBITDA Margin %. This puts The Consultant & Investment Group in the upper half of its industry. The industry median EBITDA Margin % is 10.21. The Consultant & Investment Group's value of 15.28% is 49.7% above this benchmark. While the company's 10-year median is 10.07 vs. the industry median of 10.21, The Consultant & Investment Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Consultant & Investment Group's current EBITDA Margin % of 15.28% is 49.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on The Consultant & Investment Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Consultant & Investment Group's current EBITDA Margin % is 15.28%, which is 52% above median its own 10-year median of 10.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Consultant & Investment Group stock overvalued right now?
Based on GuruFocus' analysis, The Consultant & Investment Group (AMM:CICO) is currently considered Modestly Undervalued. The stock's GF Value™ is JOD2.20, compared to a current price of JOD1.78 — trading 19.1% below its estimated fair value. The current EBITDA Margin % is 15.28%, which is 52% above median its 10-year median of 10.07 and 49.7% above the Healthcare Providers & Services industry median of 10.21. The Consultant & Investment Group's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For The Consultant & Investment Group (AMM:CICO), the current EBITDA Margin % is 15.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Consultant & Investment Group (AMM:CICO) Overvalued in 2026?
Based on GuruFocus' analysis, The Consultant & Investment Group stock appears to be undervalued.
The current stock price of JOD1.78 is trading 19.1% below its estimated GF Value™ of JOD2.20.
GuruFocus considers The Consultant & Investment Group to be Modestly Undervalued.
Key valuation signals for AMM:CICO:
EBITDA Margin %: 15.28% (52% above median its 10-year median of 10.07)
GF Value™: JOD2.20 vs. price of JOD1.78 (19.1% below fair value)
Industry Position: 49.7% above the Healthcare Providers & Services median (#218 of 668)
No single metric tells the full story. See the AMM:CICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Consultant & Investment Group Business Description
The Consultant & Investment Group is a Jordan-based company that engages in the healthcare and medical sector. It is engaged in the provision of medical care services. The company generates revenue from medical services and the sale of medicine and medical/ supplies are recognized. The company gains majority of revenue from Jordan. The Group principally operates only in the Hashemite Kingdom of Jordan.
77GF Score
Get the complete analysis for AMM:CICO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:CICO has been successfully added to your 
